Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)GlobeNewsWire • 06/01/21
Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/26/21
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/17/21
Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA ProcurementGlobeNewsWire • 05/17/21
Paratek Offers Long-Term Value Potential In The Difficult Antibiotic BusinessSeeking Alpha • 04/27/21
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/24/21
Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 MillionGlobeNewsWire • 02/24/21
Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/18/21
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021GlobeNewsWire • 02/17/21
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOsSeeking Alpha • 01/10/21
Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC GroupGlobeNewsWire • 01/04/21
Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare ConferenceGlobeNewsWire • 11/12/20
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/29/20
Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020GlobeNewsWire • 10/27/20
Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020GlobeNewsWire • 10/21/20
Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20